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Susceptibility to amoxycillin–clavulanate
among clinical isolates of Escherichia coli
resistant to cefoxitin
In a previous article published recently in CMI [1],
it was shown that all clinical isolates of Escherichia
coli resistant to cefoxitin were also resistant to
amoxycillin–clavulanate. In contrast, preliminary
results from a study performed in Seville (Spain)
indicated that 34.4% of cefoxitin-resistant clinical
isolates of E. coli remained susceptible to amoxy-
cillin–clavulanate (43rd Interscience Conference
on Antimicrobial Agents and Chemotherapy,
abstract C2-97). Resistance to cefoxitin in clinical
isolates of E. coli has been associated with hyper-
production of chromosomal or plasmid-borne
AmpC-type b-lactamases [1–3]. Clavulanic acid
is not a good substrate for these enzymes, so it
might be expected that strains of E. coli overpro-
ducing AmpC b-lactamase would be resistant to
cefoxitin and amoxycillin–clavulanate. We would
like to report on the frequency of these resistance
phenotypes among isolates of E. coli from hospi-
tals located in Europe, Asia and America that are
included in the Sentry Antimicrobial Surveillance
Program.
MICs of cefoxitin and amoxycillin–clavulanate
for 23 719 clinical isolates of E. coli (Europe,
n = 8259; Asia–West Paciﬁc, n = 3655; Latin
America, n = 3194; North America, n = 8611)
were obtained from the database of the SENTRY
Program (1997–2002). MICs were determined by
the broth microdilution reference method
according to NCCLS guidelines [4]. Isolates were
grouped as susceptible or resistant (which inclu-
ded both resistant and intermediately-resistant
isolates). Overall resistance to cefoxitin and
amoxycillin–clavulanate, respectively, was 4.8%
and 20.5% in Europe, 5.9% and 16.1% in North
America, 8.9% and 22.8% in Latin America, and
10.5% and 22.1% in Asia–West Paciﬁc. Table 1
shows the frequencies of the four possible
phenotypic combinations of susceptibility–resist-
ance to cefoxitin and amoxycillin–clavulanate.
The frequencies of the four phenotypes in Eur-
ope were similar to those for isolates from North
America, Latin America and the Asia-Paciﬁc
regions. As has been observed in previous
studies [5,6], susceptibility to amoxycillin–clavul-
anate was more common among cefoxitin-sus-
ceptible isolates than among cefoxitin-resistant
isolates of E. coli. Resistance to amoxycillin–
clavulanate was common among cefoxitin-resist-
ant isolates (67.4–70.8%). A high percentage of
cefoxitin-resistant isolates remained susceptible
to amoxycillin–clavulanate, suggesting that a
new phenotype of resistance to cefoxitin is
emerging worldwide. Although the mechan-
ism(s) of resistance to cefoxitin (possibly invol-
ving changes in outer-membrane proteins or
altered penicillin-binding proteins) in E. coli
isolates with this phenotype is currently under
investigation, it cannot be explained simply by
the hyperproduction of AmpC, since this
enzyme, when overproduced, confers resistance
or decreased susceptibility to amoxycillin–clavul-
anate.
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Table 1. Distribution of phenotypes of susceptibility–
resistance to cefoxitin and amoxycillin–clavulanate
Area
FOX-R FOX-S
AMC-S
n (%)
AMC-R
n (%)
AMC-S
n (%)
AMC-R
n (%)
Europe 116 (29.2) 281 (70.8) 6453 (82.1) 1409 (17.9)
Asia–West Paciﬁc 125 (32.6) 258 (67.4) 2723 (83.2) 549 (16.8)
Latin America 91 (32.0) 193 (68.0) 2375 (81.6) 535 (18.4)
North America 165 (32.4) 345 (67.6) 7057 (87.1) 1044 (12.9)
FOX-R, resistance to cefoxitin; FOX-S, susceptibility to cefoxitin; AMC-R, resistance
to amoxycillin–clavulanate; AMC-S, susceptibility to amoxycillin–clavulanate.
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